REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration. It is also developing RGX-501 for the treatment of homozygous familial hypercholesterolemia, which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; and RGX-111 to treat the neurological symptoms of Mucopolysaccharidosis Type I that uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system (CNS). In addition, the company engages in the development of RGX-121 for the treatment of neurological symptoms of Mucopolysaccharidosis Type II, which uses the AAV9 vector to deliver the human iduronate-2-sulfatase gene to the CNS. Further, it licenses its NAV technology platform to other biotechnology companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone240-552-8181
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.39 million
Profitability
Miscellaneous
Employees139
Next Earnings Date2/27/2019 (Confirmed)
OptionableOptionable
Regenxbio (NASDAQ:RGNX) Frequently Asked Questions
What is Regenxbio's stock symbol?
Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."
How were Regenxbio's earnings last quarter?
Regenxbio Inc (NASDAQ:RGNX) posted its quarterly earnings results on Tuesday, May, 8th. The biotechnology company reported $3.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.00 by $2.04. The biotechnology company had revenue of $132.39 million for the quarter, compared to analyst estimates of $80 million. Regenxbio had a net margin of 44.30% and a return on equity of 22.52%. View Regenxbio's Earnings History.
When is Regenxbio's next earnings date?
What price target have analysts set for RGNX?
6 brokers have issued 1-year price objectives for Regenxbio's stock. Their forecasts range from $42.00 to $127.50. On average, they anticipate Regenxbio's share price to reach $86.75 in the next twelve months. This suggests a possible upside of 89.9% from the stock's current price. View Analyst Price Targets for Regenxbio.
What is the consensus analysts' recommendation for Regenxbio?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 1 sell rating, 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regenxbio.
What are Wall Street analysts saying about Regenxbio stock?
Here are some recent quotes from research analysts about Regenxbio stock:
- 1. According to Zacks Investment Research, "REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. " (2/6/2019)
- 2. Raymond James analysts commented, "We are maintaining our Outperform rating and raising our target price to $76 (previously was $45) for REGENXBIO, primarily driven by our increasing confidence in the company’s pipeline products and the gene therapy space as a whole as well as the inclusion of the company’s wholly owned MPS programs into our models. With two wholly owned assets poised to deliver clinical data in late 2018, a powerful AAV technology platform with >20+ partnered programs (10 of which are in the clinic), and a cash position of $311 million (pro forma), we continue to recommend REGENXBIO shares to risk-tolerant investors." (6/25/2018)
Has Regenxbio been receiving favorable news coverage?
Press coverage about RGNX stock has been trending somewhat positive recently, InfoTrie reports. The research firm rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Regenxbio earned a media sentiment score of 1.7 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the next few days.
Who are some of Regenxbio's key competitors?
Some companies that are related to Regenxbio include argenx (ARGX), Allogene Therapeutics (ALLO), Ablynx (ABLYF), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA), Crispr Therapeutics (CRSP), Alector (ALEC), Orchard Therapeutics (ORTX) and Momenta Pharmaceuticals (MNTA).
What other stocks do shareholders of Regenxbio own?
Who are Regenxbio's key executives?
Regenxbio's management team includes the folowing people:
- Mr. Kenneth T. Mills, CEO, Pres & Director (Age 44)
- Mr. Vittal K. Vasista, Chief Financial Officer (Age 51)
- Dr. Olivier Danos, Chief Scientific Officer (Age 61)
- Mr. Curran M. Simpson, Sr. VP of Technical Operations (Age 57)
- Mr. Patrick J. Christmas II, Sr. VP & Gen. Counsel (Age 48)
Who are Regenxbio's major shareholders?
Regenxbio's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (13.46%), RTW Investments LP (2.93%), Perceptive Advisors LLC (1.80%), Bank of New York Mellon Corp (1.48%), Northern Trust Corp (1.15%) and Geode Capital Management LLC (1.06%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.
Which institutional investors are selling Regenxbio stock?
RGNX stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Voloridge Investment Management LLC, Gotham Asset Management LLC, Acadian Asset Management LLC, Chicago Equity Partners LLC, MetLife Investment Advisors LLC, GAM Holding AG and Two Sigma Investments LP. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Insider Buying and Selling for Regenxbio.
Which institutional investors are buying Regenxbio stock?
RGNX stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Perceptive Advisors LLC, Bank of New York Mellon Corp, BlackRock Inc., First Trust Advisors LP, Carmignac Gestion, Geode Capital Management LLC and Squarepoint Ops LLC. View Insider Buying and Selling for Regenxbio.
How do I buy shares of Regenxbio?
Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Regenxbio's stock price today?
One share of RGNX stock can currently be purchased for approximately $45.68.
How big of a company is Regenxbio?
Regenxbio has a market capitalization of $1.64 billion and generates $10.39 million in revenue each year. The biotechnology company earns $-73,160,000.00 in net income (profit) each year or ($2.45) on an earnings per share basis. Regenxbio employs 139 workers across the globe.
What is Regenxbio's official website?
How can I contact Regenxbio?
Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]
MarketBeat Community Rating for Regenxbio (NASDAQ RGNX)
MarketBeat's community ratings are surveys of what our community members think about Regenxbio and other stocks. Vote "Outperform" if you believe RGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
